Abstract
The first-generation protease inhibitors (PIs) of hepatitis C virus (HCV), telaprevir and boceprevir, are the harbingers of important advances in the treatment of chronic HCV infection. Improved response rates have...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have